S&P 500   4,297.29 (+0.00%)
DOW   34,106.70 (+0.57%)
QQQ   331.17 (-0.57%)
AAPL   172.21 (-0.57%)
MSFT   291.82 (-0.56%)
META   178.57 (-1.28%)
GOOGL   121.26 (-0.67%)
AMZN   144.13 (+0.66%)
TSLA   916.67 (-1.22%)
NVDA   188.34 (-1.04%)
NIO   20.77 (-2.49%)
BABA   92.62 (-1.68%)
AMD   99.75 (-1.25%)
MU   63.48 (-1.89%)
T   18.59 (+1.09%)
CGC   3.77 (-1.31%)
F   16.41 (+0.55%)
GE   80.65 (+1.05%)
DIS   125.12 (+0.69%)
AMC   24.76 (+2.27%)
PYPL   101.87 (+0.35%)
PFE   49.86 (+0.22%)
NFLX   245.62 (-1.40%)
S&P 500   4,297.29 (+0.00%)
DOW   34,106.70 (+0.57%)
QQQ   331.17 (-0.57%)
AAPL   172.21 (-0.57%)
MSFT   291.82 (-0.56%)
META   178.57 (-1.28%)
GOOGL   121.26 (-0.67%)
AMZN   144.13 (+0.66%)
TSLA   916.67 (-1.22%)
NVDA   188.34 (-1.04%)
NIO   20.77 (-2.49%)
BABA   92.62 (-1.68%)
AMD   99.75 (-1.25%)
MU   63.48 (-1.89%)
T   18.59 (+1.09%)
CGC   3.77 (-1.31%)
F   16.41 (+0.55%)
GE   80.65 (+1.05%)
DIS   125.12 (+0.69%)
AMC   24.76 (+2.27%)
PYPL   101.87 (+0.35%)
PFE   49.86 (+0.22%)
NFLX   245.62 (-1.40%)
S&P 500   4,297.29 (+0.00%)
DOW   34,106.70 (+0.57%)
QQQ   331.17 (-0.57%)
AAPL   172.21 (-0.57%)
MSFT   291.82 (-0.56%)
META   178.57 (-1.28%)
GOOGL   121.26 (-0.67%)
AMZN   144.13 (+0.66%)
TSLA   916.67 (-1.22%)
NVDA   188.34 (-1.04%)
NIO   20.77 (-2.49%)
BABA   92.62 (-1.68%)
AMD   99.75 (-1.25%)
MU   63.48 (-1.89%)
T   18.59 (+1.09%)
CGC   3.77 (-1.31%)
F   16.41 (+0.55%)
GE   80.65 (+1.05%)
DIS   125.12 (+0.69%)
AMC   24.76 (+2.27%)
PYPL   101.87 (+0.35%)
PFE   49.86 (+0.22%)
NFLX   245.62 (-1.40%)
S&P 500   4,297.29 (+0.00%)
DOW   34,106.70 (+0.57%)
QQQ   331.17 (-0.57%)
AAPL   172.21 (-0.57%)
MSFT   291.82 (-0.56%)
META   178.57 (-1.28%)
GOOGL   121.26 (-0.67%)
AMZN   144.13 (+0.66%)
TSLA   916.67 (-1.22%)
NVDA   188.34 (-1.04%)
NIO   20.77 (-2.49%)
BABA   92.62 (-1.68%)
AMD   99.75 (-1.25%)
MU   63.48 (-1.89%)
T   18.59 (+1.09%)
CGC   3.77 (-1.31%)
F   16.41 (+0.55%)
GE   80.65 (+1.05%)
DIS   125.12 (+0.69%)
AMC   24.76 (+2.27%)
PYPL   101.87 (+0.35%)
PFE   49.86 (+0.22%)
NFLX   245.62 (-1.40%)
NASDAQ:TMDX

TransMedics Group - TMDX Stock Forecast, Price & News

$44.05
-3.55 (-7.46%)
(As of 08/16/2022 03:01 PM ET)
Add
Compare
Today's Range
$43.26
$47.15
50-Day Range
$25.73
$48.78
52-Week Range
$10.00
$49.27
Volume
23,322 shs
Average Volume
569,014 shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$46.00

TransMedics Group MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
5.3% Upside
$46.00 Price Target
Short Interest
Bearish
5.62% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.43mentions of TransMedics Group in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$6.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.57) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

888th out of 1,124 stocks

Electromedical Equipment Industry

19th out of 24 stocks

TMDX stock logo

About TransMedics Group (NASDAQ:TMDX) Stock

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $46.00 to $58.00 in a report on Thursday, August 4th. Cowen increased their price objective on shares of TransMedics Group from $39.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, July 26th. Oppenheimer increased their price objective on shares of TransMedics Group from $40.00 to $45.00 and gave the company an "outperform" rating in a report on Tuesday, August 2nd. JPMorgan Chase & Co. upgraded shares of TransMedics Group from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $26.00 to $48.00 in a report on Tuesday, August 2nd. Finally, Cowen raised their target price on shares of TransMedics Group from $45.00 to $50.00 in a report on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, TransMedics Group has an average rating of "Moderate Buy" and an average price target of $46.00.

TransMedics Group Price Performance

NASDAQ:TMDX traded up $0.60 during trading hours on Monday, reaching $47.60. 271,474 shares of the company's stock were exchanged, compared to its average volume of 287,839. The business's 50-day simple moving average is $34.49 and its two-hundred day simple moving average is $26.60. TransMedics Group has a 12 month low of $10.00 and a 12 month high of $49.27. The company has a quick ratio of 3.41, a current ratio of 4.18 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $1.34 billion, a P/E ratio of -27.67 and a beta of 1.63.

TransMedics Group (NASDAQ:TMDX - Get Rating) last posted its quarterly earnings data on Monday, August 1st. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.09). TransMedics Group had a negative return on equity of 74.20% and a negative net margin of 92.76%. During the same quarter last year, the business posted ($0.39) earnings per share. Sell-side analysts expect that TransMedics Group will post -1.57 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP John F. Carey sold 3,320 shares of the firm's stock in a transaction that occurred on Monday, June 27th. The shares were sold at an average price of $32.59, for a total value of $108,198.80. Following the completion of the transaction, the vice president now owns 379 shares of the company's stock, valued at approximately $12,351.61. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, VP John F. Carey sold 3,000 shares of the stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $41.27, for a total value of $123,810.00. Following the completion of the sale, the vice president now owns 771 shares in the company, valued at approximately $31,819.17. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP John F. Carey sold 3,320 shares of the stock in a transaction that occurred on Monday, June 27th. The stock was sold at an average price of $32.59, for a total transaction of $108,198.80. Following the completion of the sale, the vice president now owns 379 shares of the company's stock, valued at approximately $12,351.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 151,814 shares of company stock valued at $5,633,336. Company insiders own 8.70% of the company's stock.

Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Stock News Headlines

TransMedics Group (NASDAQ:TMDX) PT Raised to $58.00
How This Rare Metal Is Going To Solve A $173 TRILLION World Problem… And Could Benefit Investors
According to Bloomberg NEF, changing the world to "All Green Energy" could cost about $173 trillion. And without this rare metal, going green would be IMPOSSIBLE. That's why there's a literal "gold rush" to find it. (HINT: It's not electric vehicles, nuclear power, or wind energy).
1 Stock With Growth Potential
This could be one of the best stocks to consider during this bear market run.
TransMedics Group (TMDX) Scheduled to Post Earnings on Monday
4 Analysts Have This to Say About TransMedics Group
Analyst Ratings for TransMedics Group
See More Headlines
Receive TMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TransMedics Group and its competitors with MarketBeat's FREE daily newsletter.

TMDX Company Calendar

Last Earnings
8/01/2022
Today
8/16/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMDX
Fax
N/A
Employees
148
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$46.00
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+4.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-44,220,000.00
Pretax Margin
-92.65%

Debt

Sales & Book Value

Annual Sales
$30.26 million
Book Value
$2.44 per share

Miscellaneous

Free Float
25,650,000
Market Cap
$1.24 billion
Optionable
Not Optionable
Beta
1.63














TMDX Stock - Frequently Asked Questions

Should I buy or sell TransMedics Group stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransMedics Group in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TMDX shares.
View TMDX analyst ratings
or view top-rated stocks.

What is TransMedics Group's stock price forecast for 2022?

7 equities research analysts have issued twelve-month target prices for TransMedics Group's shares. Their TMDX share price forecasts range from $37.00 to $58.00. On average, they predict the company's stock price to reach $46.00 in the next twelve months. This suggests that the stock has a possible downside of 3.4%.
View analysts price targets for TMDX
or view top-rated stocks among Wall Street analysts.

How have TMDX shares performed in 2022?

TransMedics Group's stock was trading at $19.16 at the start of the year. Since then, TMDX stock has increased by 148.4% and is now trading at $47.60.
View the best growth stocks for 2022 here
.

When is TransMedics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our TMDX earnings forecast
.

How were TransMedics Group's earnings last quarter?

TransMedics Group, Inc. (NASDAQ:TMDX) announced its quarterly earnings results on Monday, August, 1st. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.09. TransMedics Group had a negative trailing twelve-month return on equity of 74.20% and a negative net margin of 92.76%. During the same quarter in the prior year, the company posted ($0.39) EPS.

What guidance has TransMedics Group issued on next quarter's earnings?

TransMedics Group updated its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $67.00 million-$75.00 million, compared to the consensus revenue estimate of $66.97 million.

What is Waleed Hassanein's approval rating as TransMedics Group's CEO?

17 employees have rated TransMedics Group Chief Executive Officer Waleed Hassanein on Glassdoor.com. Waleed Hassanein has an approval rating of 83% among the company's employees.

What other stocks do shareholders of TransMedics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TransMedics Group investors own include Advanced Micro Devices (AMD), Roku (ROKU), AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Raytheon Technologies (RTX), Yamana Gold (AUY), B2Gold (BTG), Beyond Meat (BYND) and Walt Disney (DIS).

When did TransMedics Group IPO?

(TMDX) raised $75 million in an initial public offering (IPO) on Thursday, May 2nd 2019. The company issued 4,700,000 shares at $15.00-$17.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and Canaccord Genuity were co-managers.

What is TransMedics Group's stock symbol?

TransMedics Group trades on the NASDAQ under the ticker symbol "TMDX."

Who are TransMedics Group's major shareholders?

TransMedics Group's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), Macquarie Group Ltd. (6.50%), Credit Suisse AG (5.31%), State Street Corp (2.34%), Emerald Advisers LLC (1.42%) and Emerald Mutual Fund Advisers Trust (1.24%). Insiders that own company stock include Abrams Capital Management, LP, David Weill, Edwin M Kania Jr, James R Tobin, John F Carey, John F Carey, John F Sullivan, Stephen Gordon, Tamer I Khayal, Tamer I Khayal and Waleed H Hassanein.
View institutional ownership trends
.

How do I buy shares of TransMedics Group?

Shares of TMDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransMedics Group's stock price today?

One share of TMDX stock can currently be purchased for approximately $47.60.

How much money does TransMedics Group make?

TransMedics Group (NASDAQ:TMDX) has a market capitalization of $1.34 billion and generates $30.26 million in revenue each year. The company earns $-44,220,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does TransMedics Group have?

The company employs 148 workers across the globe.

How can I contact TransMedics Group?

TransMedics Group's mailing address is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. The official website for the company is www.transmedics.com. The company can be reached via phone at (978) 552-0900 or via email at investors@transmedics.com.

This page (NASDAQ:TMDX) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.